Fluorescent probes for α-synuclein biomarkers: Innovations in early diagnosis and therapeutic monitoring of Parkinson's disease
文献类型：期刊论文
| 作者 | Li, Qun3,4; Song, Siqi2; Song, Zefeng2; Shah, Pir Tariq2,3; Zhang, Qiuchi3,4; Yang, Yitong3; Tan, Xin3; Wang, Jianshe4; Wu, Zhenyong1,3,4 |
| 刊名 | CLINICA CHIMICA ACTA
 |
| 出版日期 | 2026-01-15 |
| 卷号 | 579页码:11 |
| 关键词 | Parkinson's disease Alpha-synuclein Fluorescent probes Early diagnosis |
| ISSN号 | 0009-8981 |
| DOI | 10.1016/j.cca.2025.120612 |
| 通讯作者 | Wang, Jianshe() ; Wu, Zhenyong(wuzhenyong@simm.ac.cn) |
| 英文摘要 | Parkinson's disease (PD), a rapidly progressing neurodegenerative disorder, underscores the critical need for early diagnostic tools to mitigate its debilitating clinical trajectory. Central to PD pathology is the aggregation of alpha-synuclein (alpha-syn), a protein whose misfolded forms drive neuronal dysfunction and serve as a hallmark biomarker. This review explores the transformative role of fluorescent probes in detecting alpha-syn aggregates and other PD-related biomarkers, offering unprecedented sensitivity and specificity for early diagnosis. We systematically categorize probes into three classes, e.g., small molecules, nanomaterials, and macromolecules, detailing their design principles, mechanisms, and applications in real-time monitoring of alpha-syn fibrillation, dopamine metabolism, and oxidative stress pathways. Key advancements, such as the PP-BTA series for dual A beta/alpha-syn detection and NIR-Lyso-FA for formaldehyde imaging, highlight the integration of multidisciplinary technologies to overcome current diagnostic limitations. Furthermore, we evaluate preclinical successes in animal models and emerging strategies for clinical translation, including high-throughput screening and multimodal imaging. By addressing challenges in probe standardization, biocompatibility, and scalability, this review provides a roadmap for advancing fluorescent probes from laboratory innovation to clinical utility, ultimately enhancing personalized therapeutic strategies and improving the quality of life for PD patients. |
| WOS关键词 | LEWY BODIES ; QUANTUM DOTS ; NITRIC-OXIDE ; NEURODEGENERATION ; DOPAMINE ; DEMENTIA ; PROTEIN ; RISK ; AGGREGATION ; ALZHEIMERS |
| 资助项目 | Key R&D Program of Shandong Province, China[2024CXPT029] ; Key R & D Program of Shandong Province, China ; National Natural Science Foundation of China[32371283] ; Taishan Scholars Program[2023000027] ; Taishan Scholars Program[2023000090] ; Special Supporting Funds for Leading Talents at or Above the Provincial Level in Yantai City[2023000090] |
| WOS研究方向 | Medical Laboratory Technology |
| 语种 | 英语 |
| WOS记录号 | WOS:001578984800001 |
| 出版者 | ELSEVIER |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/320692]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Wang, Jianshe; Wu, Zhenyong |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China 2.Dalian Univ Technol, Fac Med, Dalian 116081, Liaoning, Peoples R China 3.Bohai Rim Adv Res Inst Drug Discovery, Shandong Lab Yantai Drug Discovery, Yantai 264117, Shandong, Peoples R China 4.Yantai Univ, Minist Educ, Sch Pharm, Key Lab Mol Pharmacol & Drug Evaluat, Yantai 264005, Peoples R China |
| 推荐引用方式 GB/T 7714 | Li, Qun,Song, Siqi,Song, Zefeng,et al. Fluorescent probes for α-synuclein biomarkers: Innovations in early diagnosis and therapeutic monitoring of Parkinson's disease[J]. CLINICA CHIMICA ACTA,2026,579:11. |
| APA | Li, Qun.,Song, Siqi.,Song, Zefeng.,Shah, Pir Tariq.,Zhang, Qiuchi.,...&Wu, Zhenyong.(2026).Fluorescent probes for α-synuclein biomarkers: Innovations in early diagnosis and therapeutic monitoring of Parkinson's disease.CLINICA CHIMICA ACTA,579,11. |
| MLA | Li, Qun,et al."Fluorescent probes for α-synuclein biomarkers: Innovations in early diagnosis and therapeutic monitoring of Parkinson's disease".CLINICA CHIMICA ACTA 579(2026):11. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。